Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568340 | 0.97 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL360400 | 0.97 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAGAAMAPT | |
| Hydrochloric Acid SCHEMBL5621296 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL139002 | 0.82 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL12968545 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KDM4ELMNAGAAMAPT | |
| Bromide SCHEMBL29858695 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL28908462 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL30578152 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAGAAMAPT | |
| Methane SCHEMBL2038793 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL30578150 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621101-A | Refining method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 李冰坚 | 2022-06-14 | — | — | CN | claimed |
| CN-114621096-A | Synthetic method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 余购粮 | 2022-06-14 | — | — | CN | claimed |
| US-20160159775-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-09 | — | — | US | claimed |
| EP-2964229-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2016-01-13 | — | — | EP | claimed |
| US-20140364607-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-11 | — | — | US | claimed |
| WO-2014138368-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-12 | — | — | WO | claimed |
| US-20140256942-A1 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | JANSSEN PHARMACEUTICA NV (US) | 2014-09-11 | — | — | US | claimed |
| CN-114621101-A | Refining method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 李冰坚 | 2022-06-14 | — | — | CN | disclosed |
| CN-114621096-A | Synthetic method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 余购粮 | 2022-06-14 | — | — | CN | disclosed |
| CN-114621096-A | Synthetic method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 余购粮 | 2022-06-14 | — | — | CN | disclosed |
| CN-114621096-A | Synthetic method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 余购粮 | 2022-06-14 | — | — | CN | disclosed |
| CN-114621101-A | Refining method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 李冰坚 | 2022-06-14 | — | — | CN | disclosed |
| CN-114621101-A | Refining method of 3, 5-dimethyl-1, 2-phenylenediamine dihydrochloride | 李冰坚 | 2022-06-14 | — | — | CN | disclosed |
| EP-0946533-A1 | PROCESS FOR PREPARING 2,1,3-BENZOTHIADIAZOLES | BAYER AG (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027076-A1 | PROCESS FOR PREPARING 2,1,3-BENZOTHIADIAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-06-25 | — | — | WO | disclosed |
| EP-0012909-B1 | BENZIMIDAZOLYL-2-ALKANE-PHOSPHONIC ACIDS AND THEIR SALTS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS CORROSION INHIBITORS OR WETTING AGENTS | BAYER AG (DE) | 1983-06-15 | — | — | EP | disclosed |
| US-4278791-A | CORROSION RESISTANCE, WETTING AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
| EP-0012909-A1 | Benzimidazolyl-2-alkane-phosphonic acids and their salts, process for their preparation and their use as corrosion inhibitors or wetting agents | BAYER AG (DE) | 1980-07-09 | — | — | EP | disclosed |
| US-4104194-A | 1,2-FUSED 5- OR 6-MEMBERED 1,3-DINITROGEN HETEROCYCLIC COMPOUNDS AS ANTICORROSION AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-08-01 | — | — | US | disclosed |
| US-4048174-A | ANTI-CORROSION AGENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364607-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | GAA 3646/4885ALDH1A1 3785/4885KDM4E 1292/4885 |
| US-20140256942-A1 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | HRH4, HRH3, HRH2 | GAA 3646/4885ALDH1A1 3785/4885KDM4E 1292/4885 |
| US-20160159775-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | GAA 3646/4885ALDH1A1 3785/4885KDM4E 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.